Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: A report of Japan Clinical Oncology Group Study (JCOG 9601)

Japanese Journal of Clinical Oncology

Volumn 31, Issue 10, 2001, Pages 488-494

  Tsuchiya, Satoshi ^b   Ohe, Yuichiro ^a   Sugiura, Takahiko ^c   Fuwa, Nobukazu ^c   Kitamoto, Yoshizumi ^d   Mori, Kiyoshi ^e   Kobayashi, Hideo ^f   Nakata, Koichiro ^g   Sawa, Toshiyuki ^h   Hirai, Kazuya ⁱ   Etoh, Takashi ^j   Saka, Hideo ^k   Saito, Atsushi ^l   Fukuda, Haruhiko ^m   Ishizuka, Naoki ^m   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Department of Surgery   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d GUNMA UNIVERSITY   (Japan)

^e TOCHIGI CANCER CENTER   (Japan)

^f NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^g TORANOMON HOSPITAL   (Japan)

^h Gifu Municipal Hospital   (Japan)

ⁱ Nagano Municipal Hospital   (Japan)

^j SHIZUOKA GENERAL HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^l UNIVERSITY OF THE RYUKYUS   (Japan)

^m NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

more..

Author keywords

Chemoradiotherapy; Cisplatin; Non small cell lung cancer; Phase I study; Vindesine

Indexed keywords

BILIRUBIN; CISPLATIN; VINDESINE;

ACCELERATION; ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG EFFECT; ESOPHAGITIS; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPOXIA; LEUKOPENIA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; STANDARD; THROMBOCYTOPENIA; TOXICITY; TREATMENT PLANNING;

EID: 0034760979     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye106     Document Type: Article

References (21)

1. The survival of patients with inoperable lung cancer: A large-scale randomized study of radiation therapy versus placebo
2. Impact of tumor control on survival in carcinoma of the lung treated with irradiation
3. Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung
4. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy
5. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: A retrospective multivariate analysis
6. Inoperable non-small cell lung cancer: A retrospective analysis of 427 patients treated with high-dose radiotherapy
7. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): Long-term results
8. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomised multicentre trial. CHART Steering Committee
9. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung carcinoma: Results of a North Central Cancer Treatment Group Phase III Study
10. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
11. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer
12. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
13. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer
14. Reporting results of cancer treatment
15. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group
16. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: Long-term follow-up results of RTOG 83-13
17. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410
18. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results Japan Clinical Oncology Group Protocol 8902
19. Retrospective comparison of the effect and the toxicity of QD (JCOG8902) and BID (JCOG9201) concurrent RT with CT (CDDP + VDS) in locally advanced non-small cell lung cancer (NSCLC)
20. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer
21. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer